CALCIPHYLAXIS TREATMENT MARKET ANALYSIS

Calciphylaxis or calcific uremic arteriolopathy is a syndrome of vascular calcification, thrombosis, and skin necrosis. It mostly occurs in patients with end-stage kidney disease or kidney transplant. Calciphylaxis results in chronic non-healing wounds and is usually fatal. It has a high mortality rate, owing to cardiovascular disease and sepsis caused due to infected skin ulcers. The exact pathogenetic mechanisms of the disease is not known. Most patients with the condition have abnormalities in blood-clotting factors. Multiple interventions are used to treat calciphylaxis, including restoring oxygen and blood flow to the skin, decreasing calcium deposits, and intensive wound treatment.

Market Dynamics

High prevalence of kidney diseases and increasing number of clinical trials in the field of calciphylaxis treatment are major factors expected to drive growth of the calciphylaxis treatment market. According to the National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center, in 2016, the overall prevalence of chronic kidney diseases in the U.S. was around 14% of total population.

Calciphylaxis has no approved treatment, which has led to increasing number of clinical trials and research, which is expected to fuel growth of the market. For instance, in March 2015, the Multidisciplinary Calciphylaxis Program launched the first randomized trial for treatment of calciphylaxis with research focus on the role of vitamin K in the treatment of the disease.

Lack of an appropriate treatment for calciphylaxis is a major obstacle in the calciphylaxis treatment market growth. However, key players in the market are focused on identifying the root cause of the disease and its associated treatment in order to gain market share. For instance, according to a study published by the American Journal of Nephrology, in June 2018, apixaban, an anticoagulant used to treat venous thromboembolic events, can be a safe and effective alternative to warfarin in patients with End-Stage Renal Disease (ESRD) on dialysis suffering from calciphylaxis.

Key features of the study:

• This report provides in-depth analysis of the global calciphylaxis treatment market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global calciphylaxis treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include, 3M, Amgen Inc., BSN Medical, ConvaTec Inc., Medtronic Plc., Smith & Nephew Plc., and Laboratoris Sanifit S.L.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global calciphylaxis treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for calciphylaxis treatment market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

• Global Calciphylaxis Treatment Market, By Treatment:
• Drug Therapy
• Hyperbaric Oxygen Therapy
• Global Calciphylaxis Treatment Market, By End User:
• Hospital and Clinics
• Homecare
• Ambulatory Centers
• Global Calciphylaxis Treatment Market, By Region:
• North America
• By Country:
• U.S.
• Canada
• By Treatment:
• Drug Therapy
• Hyperbaric Oxygen Therapy
• By End User:
• Hospital and Clinics
• Homecare
• Ambulatory Centers
• Europe
• By Country:
• U.K.
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe
• By Treatment:
• Drug Therapy
• Hyperbaric Oxygen Therapy
• By End User:
• Hospital and Clinics
• Homecare
• Ambulatory Centers
• Asia Pacific
• By Country:
• Australia
• India
• China
• Japan
• ASEAN
• South Korea
• Rest of Asia Pacific
• By Treatment:
• Drug Therapy
• Hyperbaric Oxygen Therapy
• By End User:
• Hospital and Clinics
• Homecare
• Ambulatory Centers
• Latin America
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• By Treatment:
• Drug Therapy
• Hyperbaric Oxygen Therapy
• By End User:
• Hospital and Clinics
• Homecare
• Ambulatory Centers
• Middle East
• By Country:
• GCC
• Israel
• Rest of Middle East
• By Treatment:
• Drug Therapy
• Hyperbaric Oxygen Therapy
• By End User:
• Hospital and Clinics
• Homecare
• Ambulatory Centers
• Africa
• By Country:
• South Africa
• Central Africa
• North Africa
• By Treatment:
• Drug Therapy
• Hyperbaric Oxygen Therapy
• By End User:
• Hospital and Clinics
• Homecare
• Ambulatory Centers
• Company Profiles
• 3M*
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
• Amgen Inc.
• BSN Medical
• ConvaTec Inc.
• Medtronic Plc.
• Smith & Nephew Plc.
• Laboratoris Sanifit S.L.

“*” marked represents similar segmentation in other categories in the respective section.